Pfizer and biontech commence global clinical trial to evaluate covid-19 vaccine in pregnant women

New york, usa and mainz, germany, february 18, 2021 — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) announced today that the first participants have been dosed in a global phase 2/3 study to further evaluate the safety, tolerability, and immunogenicity of the pfizer-biontech covid-19 vaccine (bnt162b2) in preventing covid-19 in healthy pregnant women 18 years of age and older.     “we are proud to start this study in pregnant women and continue to gather the evidence on safety and efficacy to potentially support the use of the vaccine by important subpopulations,” said william gruber m.d., senior vice president of vaccine clinical research and development, pfizer. “pregnant women have an increased risk of complications and developing severe covid-19, which is why it is critical that we develop a vaccine that is safe and effective for this population. we are deeply thankful to the volunteers who are enrolling in the trial, and site investigators who are leading this work.”
BNTX Ratings Summary
BNTX Quant Ranking